Dynavax Technologies

Company snapshot

Dynavax, a Sanofi Company, is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caus

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Dynavax Technologies. Not investment advice.

• What is Dynavax Technologies?

  Dynavax International is a pharma organization headquartered in EU. Primary therapeutic focus areas include Shingles. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• Is Dynavax Technologies publicly traded?

  Dynavax Technologies appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Dynavax Technologies develop or market?

  We link 1 drug profile(s) where Dynavax Technologies is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/dynavax-international-b-v#company-drugs.

• What are the latest developments for Dynavax Technologies?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Dynavax Technologies focus on?

  Dynavax Technologies focuses on Shingles based on our analysis of their pipeline programs and drug development activities.